Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Patent
1996-03-14
1998-10-06
Daus, Donald G.
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
514284, A61K 3158
Patent
active
058178180
DESCRIPTION:
BRIEF SUMMARY
This application is filed pursuant to 35 U.S.C. .sctn. 371 as a U.S. National Phase Application of International Application Ser. No. PCT/US94/10479 filed Sep. 16, 1994 which claims priority from U.S. Ser. No. 08/123,280 filed Sep. 17, 1993, abandoned and U.S. Ser. No. 08/136,515 filed Oct. 12, 1993, abandoned.
The present invention relates to certain substituted 17.beta.-anilide-4-aza-5.alpha.-androstan-3-ones, in particular as surprisingly potent and selective dual inhibitors of type 1 and 2 human 5.alpha.-reductase.
BACKGROUND OF THE INVENTION
Androgens are responsible for many physiological functions in both males and females. Androgen action is mediated by specific intracellular hormone receptors expressed in androgen responsive cells. Testosterone, the major circulating androgen, is secreted by Leydig cells of the testes under the stimulation of pituitary-derived luteinizing hormone (LH). However, reduction of the 4, 5 double bond of testosterone to dihydrotestosterone (DHT) is required in some target tissues, such as prostate and skin, for androgen action. Steroid 5.alpha.-reductases in target tissues catalyze conversion of testosterone to DHT in an NADPH dependent fashion as shown in Scheme A. ##STR2##
The requirement for DHT to act as an agonist in these target tissues has been highlighted by studies of steroid 5.alpha.-reductase deficient individuals who have vestigial prostate glands and do not suffer from acne vulgaris or male pattern baldness (see McGinley, J. et al., The New England J. of Medicine, 300, 1233 (1979)). Thus, inhibition of the conversion of testosterone to DHT in these target tissues is anticipated to be useful in the treatment of a variety of androgen responsive diseases, e.g., benign prostatic hyperplasia, prostate cancer, acne, male pattern baldness and hirsutism.
Additionally, it has recently been discovered that two isozymes of 5.alpha.-reductase exist in humans which differ in their tissue distribution, affinity for testosterone, pH profile and sensitivity to inhibitors (see Russell, D. W. et al., J. Clin. Invest., 89, 293 (1992); Russell, D. W. et al., Nature, 354, 159 (1991)). The steroid 5.alpha.-reductase deficient individuals studied by Imperato-McGinley are deficient in the type 2, 5.alpha.-reductase enzyme (Russell, D. W. et al., J. Clin. Invest., 90, 799 (1992); Russell, D. W. et al., New England J. Med., 327, 1216 (1992)), which is the predominant isozyme present in the prostate, while the type 1 isozyme is predominant in the skin. The relative value of isozyme specific and dual inhibitors of the two isozymes of 5.alpha.-reductase will depend upon the type of disease treated (benign prostatic hyperplasia, prostate cancer, acne, male pattern baldness or hirsutism) as well as the stage of the disease (prevention versus treatment) and the anticipated side-effects in the intended patients (for example treatment of acne vulgaris in pubescent males).
Because of their valuable therapeutic potential, testosterone inhibitors"! have been the subject of active research worldwide. For example, see: Hsia, S. and Voight, W., J. Invest. Derm., 62, 224 (1973); Robaire, B. et al., J. Steroid Biochem., 8, 307 (1977); Petrow, V. et al., Steroids, 38, 121 (1981); Liang, T. et al., J. Steroid Biochem., 19, 385 (1983); Holt, D. et al., J. Med. Chem., 33, 937 (1990); U.S. Pat. No. 4,377,584, U.S. Pat. No. 4,760,071 and U.S. Pat. No. 5,017,568. Two particularly promising 5.alpha.-reductase inhibitors are MK-906 (Merck), known by the generic name, finasteride, and marketed under the trademark, Proscar; and SKF-105657 (SmithKline Beecham), shown in Scheme B. ##STR3##
The potent inhibition of bovine adrenal and porcine granulosa cell 3.beta.-hydroxy-.DELTA..sup.5 -steroid dehydrogenase/3-keto-.DELTA..sup.5 -steroid isomerase (3BHSD) by the 4-azasteroid derivative, 4-MA, shown in Scheme C and not by the drug finasteride ##STR4## (Tan, C. H.; Fong, C. Y.; Chan, W. K. Biochem. Biophys. Res. Comm., 144, 166 (1987) and Brandt, M.; Levy, M. A. Biochemistry, 28, 140 (1989)) along with the criti
REFERENCES:
patent: 4377584 (1983-03-01), Rasmusson et al.
patent: 4760071 (1988-07-01), Rasmusson et al.
patent: 5017568 (1991-05-01), Holt et al.
patent: 5084574 (1992-01-01), Bhattacharya et al.
patent: 5098908 (1992-03-01), Steinberg et al.
patent: 5215894 (1993-06-01), Arison et al.
patent: 5565467 (1996-10-01), Batchelor et al.
Frye et al, Jour. Med. Chem. vol. 38 pp. 2621-2627 (Jul. 1995).
Rasmusson, et al., J. Med. Chem., 29, 1986, pp. 2298-2315, "Steroids: Structure-Activity Relationships for Inhibition of 5.alpha.-Reductase and Androgen Receptor Binding".
Rasmusson, et al., J. of Med. Chem., 27, 1984, pp. 1690-1701, "Azasteroids a Inhibitors of Rat Prostatic 5.alpha.-Reductase".
Imperato, et al., IG, 1986, 130-133, "Inherited 5.alpha.-Reductase Deficiency in Man".
Jones, et al., British J. of Urology, 66, 1990, pp. 506-508, "Origin and Structure of Benign Prostatic Hyperplasia".
Blakitnyi, et al., J. of Organic Chem., vol. 10, No. 3,1974, pp. 512-516, "Synthesis of the Analogs of 3-p-Menthanol With a Fluorinated Methyl Group."
Reetz, et al., Angew. Chem. Int. Ed. Engl., vol. 19, No. 11, 1980, pp. 900-901, "Geminal Dialkylation of Ketones with Grignard Compounds and Methyltitanium(IV) Chlorides."
McGinley, et al., New England Journal of Medicine, 300, 1979, pp. 1233-1237.
Robaire, et al., J. Steroid Biochem., 8, 1977, pp. 307-310.
Petrow, et al., Steroids, 38, 1981, p. 121.
Liang, et al., J. Steroid Biochem., 19, 1983, pp. 385-390.
Holt, et al, J. Med. Chem., 33, 1990, 937-942 "Steroidal A Ring Aryl Carboxylic Acids: A New Class of Steroid 5-Reductase Inhibitors".
Davies, H.W., et al., Tetrahedron Letters, vol. 30, No. 38, 1989, pp. 5057-5060, "Stereoselective Cyclopropanations with Vinylcarbenoids".
Baum, et al., Synthetic Communications, vol. 17, No. 14, 1987, pp. 1709-1716, "Diazotransfer Reactions with p-Acetamidobenzenesulfonyl Azide".
He, et al., J. Med. Chem., 36, 1993, pp. 1188-1193, "Synthesis and Homologues at Dopamine-Uptake and Phencyclidine-and .sigma.-Binding Sites".
Stoner, et al., J. Steroid Biochem. Molec. Biol., vol. 37, 1990, pp. 375-378.
Brooks, et al., Steroids, 47, 1986, p. 1, "5.alpha.-Reductase Inhibitory and Anti-Androgenic Activities of Some 4-Azasteroids in the Rat".
Batchelor Kenneth William
Frye Stephen Vernon
Brink Robert H.
Daus Donald G.
Glaxo Wellcome Inc.
LandOfFree
Androstenones does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Androstenones, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Androstenones will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-79487